We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+10.83%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.37B
AUM Growth
+$618M
Cap. Flow
+$498M
Cap. Flow %
7.82%
Top 10 Hldgs %
71.12%
Holding
53
New
7
Increased
13
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$224M
2
XLRN
Acceleron Pharma
XLRN
+$131M
3
FOLD
Amicus Therapeutics
FOLD
+$53.5M
4
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
5
NUVL
Nuvalent
NUVL
+$36.5M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$108M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$38.4M
3
RLMD icon
Relmada Therapeutics
RLMD
+$29.9M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$24.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$36.8M 0.58%
3,235,000
– –
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.98B
$36.5M 0.57%
2,200,000
-241,658
-10% -$4.66M
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$36.3M 0.57%
1,068,000
– –
AMRN
29
Amarin Corp
AMRN
$303M
$30.6M 0.48%
300,000
– –
PRAX icon
30
Praxis Precision Medicines
PRAX
$9.93B
$29.6M 0.46%
106,667
– –
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.78B
$29.5M 0.46%
1,545,000
-1,455,000
-49% -$24.2M
RNAM
32
DELISTED
Avidity Biosciences
RNAM
$28.3M 0.44%
1,150,000
+605,000
+111% +$13.1M
KYMR icon
33
Kymera Therapeutics
KYMR
$8.82B
$26.8M 0.42%
+455,750
New +$26.4M
DICE
34
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$26.2M 0.41%
+800,000
New +$27.2M
BIIB icon
35
Biogen
BIIB
$30.3B
$23.8M 0.37%
+84,000
New +$27.5M
AVDL
36
DELISTED
Avadel Pharmaceuticals
AVDL
$22.3M 0.35%
2,275,000
-2,090,000
-48% -$16.5M
NUVL
37
DELISTED
Nuvalent
NUVL
$22.3M 0.35%
+1,257,671
New +$36.5M
DSGN icon
38
Design Therapeutics
DSGN
$859M
$21.6M 0.34%
1,468,318
– –
TNGX icon
39
Tango Therapeutics
TNGX
$4.43B
$20M 0.31%
1,550,000
+750,000
+94% +$8.99M
FENC icon
40
Fennec Pharmaceuticals
FENC
$392M
$15.7M 0.25%
1,670,000
– –
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
$15.1M 0.24%
695,000
– –
MRUS
42
DELISTED
Merus
MRUS
$9.9M 0.16%
450,000
-210,000
-32% -$4.5M
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.76M 0.15%
5,084,184
– –
SRPT icon
44
CALL
Sarepta Therapeutics
SRPT
$1.75B
$2.19M 0.03%
+200,000
New +$15.4M
IOVA icon
45
CALL
Iovance Biotherapeutics
IOVA
$2.69B
$1.54M 0.02%
+650,000
New +$15.3M
APLS
46
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$1.26M 0.02%
1,515,000
+1,275,000
+531% +$71.6M
XLRN
47
CALL
DELISTED
Acceleron Pharma
XLRN
$32K ﹤0.01%
+476,100
New +$62.3M
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,024,400
Closed -$8.62M
ALNY icon
49
CALL
Alnylam Pharmaceuticals
ALNY
$28.7B
– –
-150,000
Closed -$1.43M
CNTA
50
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-500,000
Closed -$11.1M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Avoro Capital Advisors held 53 positions worth $6.37B, up 11% from $5.75B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors deployed $498M of net new capital in Q3 2021, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Nuvalent: 1,257,671 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $38.4M trimmed.

  • Avoro Capital Advisors's largest Q3 2021 buy was Nuvalent: 1,257,671 shares worth $22.3M.
  • Avoro Capital Advisors added most to Apellis Pharmaceuticals in Q3 2021, an estimated $224M increase.
  • Avoro Capital Advisors's biggest Q3 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $38.4M.
  • Avoro Capital Advisors fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $108M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $6.37B portfolio in Q3 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 6 in Q3 2021.
  • Avoro Capital Advisors's portfolio value rose 11% quarter-over-quarter to $6.37B.

Based on Avoro Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.